Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More
AUROBINDO PHARMA | WOCKHARDT | AUROBINDO PHARMA/ WOCKHARDT |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 18.0 | -89.4 | - | View Chart |
P/BV | x | 3.9 | 2.0 | 196.4% | View Chart |
Dividend Yield | % | 0.3 | 0.0 | 13,897.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
WOCKHARDT Mar-18 |
AUROBINDO PHARMA/ WOCKHARDT |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 1,012 | 82.0% | |
Low | Rs | 527 | 532 | 99.2% | |
Sales per share (Unadj.) | Rs | 333.9 | 355.9 | 93.8% | |
Earnings per share (Unadj.) | Rs | 40.4 | -60.3 | -67.0% | |
Cash flow per share (Unadj.) | Rs | 51.8 | -46.8 | -110.7% | |
Dividends per share (Unadj.) | Rs | 2.50 | 0.01 | 25,000.0% | |
Dividend yield (eoy) | % | 0.4 | 0 | 28,433.8% | |
Book value per share (Unadj.) | Rs | 237.1 | 257.8 | 92.0% | |
Shares outstanding (eoy) | m | 585.91 | 110.63 | 529.6% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 2.2 | 93.7% | |
Avg P/E ratio | x | 16.8 | -12.8 | -131.3% | |
P/CF ratio (eoy) | x | 13.1 | -16.5 | -79.4% | |
Price / Book Value ratio | x | 2.9 | 3.0 | 95.6% | |
Dividend payout | % | 6.2 | 0 | -37,341.1% | |
Avg Mkt Cap | Rs m | 397,569 | 85,379 | 465.7% | |
No. of employees | `000 | 17.9 | 6.3 | 285.5% | |
Total wages/salary | Rs m | 25,849 | 9,371 | 275.8% | |
Avg. sales/employee | Rs Th | 10,956.9 | 6,295.0 | 174.1% | |
Avg. wages/employee | Rs Th | 1,447.7 | 1,498.3 | 96.6% | |
Avg. net profit/employee | Rs Th | 1,324.3 | -1,066.3 | -124.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 39,369 | 496.9% | |
Other income | Rs m | 1,553 | 1,202 | 129.2% | |
Total revenues | Rs m | 197,189 | 40,571 | 486.0% | |
Gross profit | Rs m | 39,519 | 18 | 215,953.0% | |
Depreciation | Rs m | 6,680 | 1,495 | 446.7% | |
Interest | Rs m | 2,626 | 2,555 | 102.8% | |
Profit before tax | Rs m | 31,767 | -2,830 | -1,122.7% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | -3,582 | 24.6% | |
Tax | Rs m | 7,269 | 257 | 2,828.2% | |
Profit after tax | Rs m | 23,645 | -6,669 | -354.6% | |
Gross profit margin | % | 20.2 | 0 | 43,457.6% | |
Effective tax rate | % | 22.9 | -9.1 | -251.9% | |
Net profit margin | % | 12.1 | -16.9 | -71.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 33,796 | 454.6% | |
Current liabilities | Rs m | 120,429 | 26,917 | 447.4% | |
Net working cap to sales | % | 17.0 | 17.5 | 97.2% | |
Current ratio | x | 1.3 | 1.3 | 101.6% | |
Inventory Days | Days | 135 | 79 | 170.4% | |
Debtors Days | Days | 64 | 89 | 71.4% | |
Net fixed assets | Rs m | 103,909 | 39,664 | 262.0% | |
Share capital | Rs m | 586 | 553 | 105.9% | |
"Free" reserves | Rs m | 138,322 | 27,968 | 494.6% | |
Net worth | Rs m | 138,908 | 28,522 | 487.0% | |
Long term debt | Rs m | 1,800 | 21,731 | 8.3% | |
Total assets | Rs m | 264,544 | 81,620 | 324.1% | |
Interest coverage | x | 13.1 | -0.1 | -12,181.2% | |
Debt to equity ratio | x | 0 | 0.8 | 1.7% | |
Sales to assets ratio | x | 0.7 | 0.5 | 153.3% | |
Return on assets | % | 9.9 | -5.0 | -197.0% | |
Return on equity | % | 17.0 | -23.4 | -72.8% | |
Return on capital | % | 23.8 | -7.7 | -310.6% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 9,807 | 992.3% | |
Fx outflow | Rs m | 40,589 | 1,789 | 2,269.3% | |
Net fx | Rs m | 56,727 | 8,019 | 707.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 684 | 2,370.0% | |
From Investments | Rs m | -28,768 | 6,302 | -456.5% | |
From Financial Activity | Rs m | 19,191 | -7,695 | -249.4% | |
Net Cashflow | Rs m | 6,656 | -664 | -1,002.5% |
Indian Promoters | % | 54.1 | 74.5 | 72.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.0 | 2.3 | 345.7% | |
FIIs | % | 27.7 | 7.7 | 359.7% | |
ADR/GDR | % | 0.0 | 0.1 | - | |
Free float | % | 10.2 | 15.4 | 66.2% | |
Shareholders | 69,601 | 67,757 | 102.7% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: FRESENIUS KABI ONCO. DIVIS LABORATORIES ALEMBIC ALKEM LABORATORIES ELDER PHARMA
Compare AUROBINDO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More